Roche is testing another amyloid-targeting drug called gantenerumab, for which hopes of success are higher. Results from two late-stage studies are expected in the fourth quarter. Biogen, too, has a different amyloid drug in development together with partner Eisai, which recently finished submitting the treatment for accelerated Food and Drug Administration approval. Phase 3 study data for that drug are anticipated this fall.